Who
George J. Morrow
Director
Company insider
Files Form 4 as: Director, Neurocrine Biosciences; Director, Align Technology; Director, Vical; Director, Otonomy; Director, Safeway; Director, Human Genome Sciences; Exe VP, Global Commercial Ops, Amgen.
In numbers
- Trades disclosed
- 202
- Buys
- 5
- Sells
- 11
- Bought
- $363K
- Sold
- $44.7M
- Companies
- 7
- Companies where not an officer
- 6
- First trade
- 26 Oct 2000
- Last trade
- 27 May 2026
- Last filed
- 29 May 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 27 May 2026filed 29 May 2026 | NBIX Neurocrine Biosciencesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —2,567 at $0.00 | filing |
| 27 May 2026filed 29 May 2026 | NBIX Neurocrine Biosciencesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —2,567 at $0.00 | filing |
| 21 May 2026filed 21 May 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Code M | —3,318 at $0.00 | filing |
| 21 May 2026filed 21 May 2026 | NBIX Neurocrine Biosciencesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —3,318 at $0.00 | filing |
| 21 May 2026filed 21 May 2026 | NBIX Neurocrine Biosciencesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —3,318 at $0.00 | filing |
| 21 May 2026filed 21 May 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Code M | —3,318 at $0.00 | filing |
| 20 May 2026filed 22 May 2026 | ALGN Align TechnologyMedical Devices | SEC FORM 4 Code M | —1,745 at $0.00 | filing |
| 20 May 2026filed 22 May 2026 | ALGN Align Technologyoption or derivative · Medical Devices | SEC FORM 4 Code M | —1,745 at $0.00 | filing |
| 20 May 2026filed 22 May 2026 | ALGN Align Technologyoption or derivative · Medical Devices | SEC FORM 4 Code M | —1,745 at $0.00 | filing |
| 20 May 2026filed 22 May 2026 | ALGN Align TechnologyMedical Devices | SEC FORM 4 Code M | —1,745 at $0.00 | filing |
| 25 Nov 2025filed 26 Nov 2025 | NBIX Neurocrine Biosciencesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —15,000 at $0.00 | filing |
| 25 Nov 2025filed 26 Nov 2025 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Code M | $718K15,000 at $47.89 | filing |
| 25 Nov 2025filed 26 Nov 2025 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Sold | $2.2M15,000 at $143.37 | filing |
| 22 May 2025filed 22 May 2025 | NBIX Neurocrine Biosciencesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —2,869 at $0.00 | filing |
| 22 May 2025filed 22 May 2025 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Code M | —2,869 at $0.00 | filing |
| 21 May 2025filed 22 May 2025 | NBIX Neurocrine Biosciencesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —3,318 at $0.00 | filing |
| 21 May 2025filed 22 May 2025 | ALGN Align Technologyoption or derivative · Medical Devices | SEC FORM 4 Code M | —1,148 at $0.00 | filing |
| 21 May 2025filed 22 May 2025 | ALGN Align Technologyoption or derivative · Medical Devices | SEC FORM 4 Code A | —1,745 at $0.00 | filing |
| 21 May 2025filed 22 May 2025 | ALGN Align TechnologyMedical Devices | SEC FORM 4 Code M | —1,148 at $0.00 | filing |
| 22 May 2024filed 24 May 2024 | ALGN Align Technologyoption or derivative · Medical Devices | SEC FORM 4 Code A | —1,148 at $0.00 | filing |
News
Contrasting Neurocrine Biosciences (NASDAQ:NBIX) and Perrigo (NYSE:PRGO)NBIX · dailypolitical.com · 10 Oct 2026
0 headlines in the last 90 days name George J. Morrow; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.